

Guillermo Keller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9256895/publications.pdf>

Version: 2024-02-01

27
papers

456
citations

858243

12
h-index

799663

21
g-index

35
all docs

35
docs citations

35
times ranked

742
citing authors

#	ARTICLE	IF	CITATIONS
1	Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial. <i>Emergency Medicine Journal</i> , 2022, 39, 88-93.	0.4	21
2	Precision Medicine in the Renin-Angiotensin System: Therapeutic Targets and Biological Variability. <i>Current Drug Targets</i> , 2020, 21, 1625-1637.	1.0	0
3	Drug-induced QT Interval Prolongation in the Intensive Care Unit. <i>Current Clinical Pharmacology</i> , 2018, 12, 210-222.	0.2	31
4	Dextropropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels. <i>Journal of Opioid Management</i> , 2018, 14, 335-344.	0.2	2
5	Simultaneous quantitation of meperidine, normeperidine, tramadol, propoxyphene and norpropoxyphene in human plasma using solid-phase extraction and gas chromatography/mass spectrometry: Method validation and application to cardiovascular safety of therapeutic doses. <i>Rapid Communications in Mass Spectrometry</i> . 2017. 31. 1519-1533.	0.7	6
6	In vivo Phenotyping Methods: Cytochrome P450 Probes with Emphasis on the Cocktail Approach. <i>Current Pharmaceutical Design</i> , 2017, 23, 2035-2049.	0.9	22
7	Meperidine-induced QTc-interval prolongation: prevalence, risk factors, and correlation to plasma drug and metabolite concentrations. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2017, 55, 275-285.	0.3	11
8	Drug-Induced QTc Interval Prolongation: A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice. <i>Current Drug Safety</i> , 2016, 11, 86-98.	0.3	23
9	A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients. <i>Current Drug Safety</i> , 2016, 11, 156-163.	0.3	17
10	Tramadol Induced QTc-Interval Prolongation: Prevalence, Clinical Factors and Correlation to Plasma Concentrations. <i>Current Drug Safety</i> , 2016, 11, 206-214.	0.3	12
11	Relative bioavailability between two teriparatide formulations in healthy volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2016, 54, 649-656.	0.3	1
12	Comparative bioavailability of two tablet formulations of emtricitabine/tenofovir in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2016, 54, 825-834.	0.3	0
13	Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. <i>European Journal of Clinical Nutrition</i> , 2015, 69, 697-702.	1.3	40
14	Age-distribution and genotype-phenotype correlation for N-acetyltransferase in Argentine children under isoniazid treatment. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 292-302.	0.3	5
15	Severe Neutropenia in a Renal Transplant Patient Suggesting an Interaction Between Mycophenolate and Fenofibrate. <i>Current Drug Safety</i> , 2012, 7, 24-29.	0.3	11
16	Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study. <i>Current Medical Research and Opinion</i> , 2011, 27, 2203-2211.	0.9	4
17	Pharmacovigilance and the Cardiovascular System: Two Sides to Every Story. <i>Current Drug Safety</i> , 2011, 6, 224-229.	0.3	6
18	Comparative Bioavailability of 2 Tablet Formulations of Levodopa/Benserazide in Healthy, Fasting Volunteers: A Single-Dose, Randomized-Sequence, Open-Label Crossover Study. <i>Clinical Therapeutics</i> , 2011, 33, 500-510.	1.1	13

#	ARTICLE	IF	CITATIONS
19	Bioequivalence of two tablet formulations of clopidogrel in healthy argentinian volunteers: A single-dose, randomized-sequence, open-label crossover study. <i>Clinical Therapeutics</i> , 2010, 32, 161-170.	1.1	25
20	Antihistamines: Past Answers and Present Questions. <i>Current Drug Safety</i> , 2010, 5, 58-64.	0.3	5
21	Mechanisms of Drug Induced QT Interval Prolongation. <i>Current Drug Safety</i> , 2010, 5, 44-53.	0.3	64
22	Prokinetic Agents and QT Prolongation: A Familiar Scene with New Actors. <i>Current Drug Safety</i> , 2010, 5, 73-78.	0.3	12
23	Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation. <i>Current Drug Safety</i> , 2010, 5, 105-111.	0.3	35
24	Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: A single-dose, randomized, open-label, crossover study. <i>Clinical Therapeutics</i> , 2008, 30, 2015-2023.	1.1	16
25	Relative bioavailability of new formulation of paracetamol effervescent powder containing sodium bicarbonate versus paracetamol tablets: a comparative pharmacokinetic study in fed subjects. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2449-2457.	0.9	10
26	Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 887-895.	1.9	27
27	Drug-related hospital admissions. <i>American Journal of Health-System Pharmacy</i> , 1976, 33, 792-795.	0.5	34